Improvement in dermatomyositis-associated muscle disease with anifrolumab
We describe radiological and symptomatic improvement in two patients with dermatomyositis with recalcitrant muscle disease following off-label treatment with anifrolumab, a monoclonal antibody targeting type I interferon receptor recently approved by the FDA and EMA for the treatment of systemic lupus erythematosus.
Authors
- Katharina Shaw (ORCID: https://orcid.org/0000-0003-0694-0987)
- Allen W. Ho (ORCID: https://orcid.org/0000-0002-5861-0552)
- Ellen Anshelevich
- Ruth Ann Vleugels (ORCID: https://orcid.org/0000-0001-8446-7115)
- Leila H. Shayegan (ORCID: https://orcid.org/0000-0002-9516-8863)
- Rochelle Castillo (ORCID: https://orcid.org/0000-0002-1704-9420)
- Avery LaChance (ORCID: https://orcid.org/0000-0001-7875-5284)
- Neda Shahriari (ORCID: https://orcid.org/0000-0001-5813-0113)
- Lorena Acevedo (ORCID: https://orcid.org/0000-0003-1562-6535)
- Ged G. Wieschhoff (ORCID: https://orcid.org/0000-0001-7631-934X)
- Nnenna Ezeh
- Fatma Dedeoğlu (ORCID: https://orcid.org/0000-0002-7516-0848)
- Yoo Jung Kim (ORCID: https://orcid.org/0000-0003-4589-5875)
Institutions
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Harvard University (US)
- University of Puerto Rico, Medical Sciences Campus (PR)
- Center for Discovery (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1093/bjd/ljaf064
- Citations
- 11
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 14.90